A comparison of practice patterns for acute myocardial infarction between hospitals in Canada and India

Indian Heart Journal

Volumn 49, Issue 1, 1997, Pages 35-41

  Anand, Sonia S ^a   Pais, Prem ^b   Pogue, Janice ^b   Yusuf, Salim ^b  

^a HGH McMaster Clinic   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; MAGNESIUM; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE;

AGED; CANADA; CASE-CONTROL STUDIES; CORONARY CARE UNITS; CROSS-CULTURAL COMPARISON; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; INDIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THROMBOLYTIC THERAPY;

EID: 0030935151     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Commission on Health Research for Development, Oxford University Press, New York, 1990
2. Krishnaswami, et al. Demands on tertiary care for cardiovascular diseases in India; analysis of data for 1960-89. Bull World Health Organ 1991; 69: 325-330
3. Jha P, Enas E, Yusuf S. Coronary artery disease in Asian Indians: prevalence and risk factors - a global perspective. Asian Am Pac Islander J Health 1993; 1: 164-175
4. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in South Asians overseas: a review. J Clin Epidemiol 1989; 43. 597-609
5. World Development Report 1993. Oxford University Press, 1993
6. Cairns J, Armstrong P, Belenkie I, et al. The Canadian Consensus Conference on Coronary Thrombolysis. Can J Cardiol 1993; 9: 559-564
7. Cairns J, Armstrong PW, Belenkie I, et al. Maximizing the benefits of thrombolytic therapy for acute myocardial infarction Can Med Assoc J 1995; 152, 819-822
8. Pais P, Pogue J, Gerstein H, et al. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet 1996; 348: 358-363
9. Reavan GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
10. Miller GJ, Beckles BL, Maude GD, et al. Ethnicity and other characteristics predictive of CHD in a developing community: principal results of the St. James survey, Trinidad. Int J Epidemiol 1989; 18: 808-817
11. Gunnar RM, Bourdillon PD, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures - Special Report. J Am Coll Cardiol, 1990; 16: 249-292
12. Gruppo Italiano per to studio dell Streptokinase Nell infarctio Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-360
14. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322
15. Wilcox RG, and the LATE Study Group. The LATE Study: Late Assessment of Thrombolyric Efficacy: double-blind, placebo-controlled trial of altepase given 6-24 hours after onset of symptoms of acute myocardial infarction. Eur Heart J 1992; 13: 423 (abstract)
16. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 230
17. ISIS-1 Collaborative Group. A randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986; ii: 57-66
18. The Beta Blocker Pooling Project Research Group. Eur Heart J 1988; 9: 8-16
19. Cairns JA, Armstrong P, Belenkie I, et al. The Canadian Consensus Conference on Coronary Thrombolysis - 1994 Update. Can J Cardiol 1994; 10: 517-529
20. GUSTO (The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) investigators. N Engl J Med 1993; 329: 673-682
21. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988; i: 1088-1092
22. ISIS Collaborative Group: ISIS-4 (Fourth International Study of Infarct Survival): a randomized trial comparing oral captopril versus placebo, oral mononitrate versus placebo, and intravenous magnesium sulphate versus control among 58,043 patients with suspected acute myocardial infarction. Lancet 1994; 345: 669-685
23. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
24. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677
25. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187
26. Cairns JA. Coronary thrombolysis: mortality trials. Can J Cardiol 1993; 9: 490-497
27. Avezum A, Pais P, Flather M, Anand S, Yusuf S. Pharmacologic treatment for myocardial infarction. Part 1: Implications of clinical trials of thrombolytic and antithrombotic therapies. Indian Heart J 1995; 47: 3-11
28. Tsuyuki RT, Gill S, Hilton J. Patterns of practice analysis for acute myocardial infarction. Can J Cardiol 1994; 10: 891-896
29. Le Feuvre CA, Connolly SJ, Cairns JA, Gent M, Roberts RS, Brent J. Comparison of mortality from acute myocardial infarction between 1980, 1987, and 1992 in a geographically-defined stable population. Can J Cardiol 1993; 9 (suppl E) (abstract)